INTELLIGENT BIO SOLUTIONS INC
For the period ended Jun 30, 2024. Filed Sep 18, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Sep 18, 2024
INBS$2.29+16.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
CONSOLIDATED BALANCE SHEETS
| * | As of June 30, | As of June 30, |
|---|---|---|
| 2024 | 2023 | |
| ASSETS | ||
| Current assets | ||
| Cash and cash equivalents | $6,304,098 | $1,537,244 |
| Accounts receivable, net | 429,704 | 293,861 |
| Inventories, net | 777,537 | 979,907 |
| Research and development tax incentive receivable | 525,332 | 498,758 |
| Other current assets | 497,572 | 552,791 |
| Total current assets | 8,534,243 | 3,862,561 |
| Property and equipment, net | 565,850 | 690,175 |
| Operating lease right of use assets | 306,744 | 546,475 |
| Intangible assets, net | 4,372,026 | 5,255,401 |
| Total assets | $13,778,863 | $10,354,612 |
| LIABILITIES AND SHAREHOLDERS’ EQUITY | ||
| Current liabilities | ||
| Accounts payable and accrued expenses | $1,704,568 | $2,610,028 |
| Current portion of operating lease liabilities | 274,834 | 223,447 |
| Current portion of deferred grant income | 2,486,668 | 2,338,057 |
| Current employee benefit liabilities | 469,381 | 358,942 |
| Current portion of notes payable | 515,282 | 353,211 |
| Total current liabilities | 5,450,733 | 5,883,685 |
| Employee benefit liabilities, less current portion | 63,615 | 24,902 |
| Operating lease liabilities, less current portion | 81,324 | 356,165 |
| Notes payable, less current portion | - | 402,862 |
| Total liabilities | 5,595,672 | 6,667,614 |
| Commitments and contingencies (Note 16) | - | - |
| Shareholders’ equity | ||
| Common stock, $0.01 par value, 100,000,000 shares authorized, 3,456,000 and 194,200 shares issued and outstanding at June 30, 2024 and 2023, respectively* | 34,557 | 1,942 |
| Treasury stock, at cost, 116 shares as of June 30, 2024 and 2023, respectively* | (1) | (1) |
| Additional paid-in capital | 60,971,740 | 46,180,112 |
| Accumulated deficit | (51,964,332) | (41,807,573) |
| Accumulated other comprehensive loss | (712,614) | (575,496) |
| Total consolidated Intelligent Bio Solutions Inc. equity | 8,329,350 | 3,798,984 |
| Non-controlling interest | (146,159) | (111,986) |
| Total shareholders’ equity | 8,183,191 | 3,686,998 |
| TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY | $13,778,863 | $10,354,612 |
| * | Common Stock has been retroactively adjusted to reflect the decreased number of shares resulting from the 1-for-12 Reverse Stock Split on January 26, 2024, throughout the consolidated financial statements unless otherwise stated. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.